Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study
The World Health Organization (WHO) classification of tumors of the central nervous system (CNS) was recently updated, restructuring solitary fibrous tumor (SFT) and hemangiopericytoma (HPC) into one combined entity. This is the first population-based study to examine outcomes of SFT/HPC based on the new WHO guidelines. The Surveillance, Epidemiology, and End Results (SEER) database (1998–2013) was queried to examine age-adjusted incidence and prognostic factors associated with overall survival in 416 surgically resected cases. Age-adjusted incidence was calculated to be 3.77 per 10,000,000 and was rising. Median survival was 155 months, with 5- and 10-year survival rates of 78 and 61%, respectively. Younger age, Asian/Pacific Islander versus white race, benign histology, tumor location, gross-total resection (GTR), and GTR plus radiation (RT) versus subtotal resection were significantly associated with survival. In multivariable analysis, older age (HR = 1.038, p < 0.0001), infratentorial location (HR = 2.019, p = 0.038), GTR (HR = 0.313, p = 0.041), and GTR + RT (HR = 0.215, p = 0.008) were independent prognostic factors. In the HPC and borderline/malignant subgroups, GTR + RT was associated with significantly increased survival compared with GTR alone (HR = 0.537, p = 0.039 and HR = 0.525, p = 0.038). After eliminating patients that died within 3 months of diagnosis, GTR + RT was still associated with an incremental increase in survival (HR = 0.238, p = 0.031) over GTR alone (HR = 0.280, p = 0.054). GTR + RT may be optimal in the management CNS HPC and SFT/HPC tumors with borderline/malignant features. This study, in combination with existing literature, warrants further investigation of adjuvant radiation through a prospective clinical trial.
KeywordsSolitary-fibrous tumor Hemangiopericytoma Central nervous system Meningeal tumor Gross-total resection Radiation therapy
We would like to thank the developers of the Surveillance, Epidemiology, and End Results program.
Compliance with ethical standards
Conflict of interest
Tony J. C. Wang reports personal fees and nonfinancial support from AbbVie, nonfinancial support from Merck, personal fees from AstraZeneca, personal fees from Doximity, nonfinancial support from Novocure, personal fees and nonfinancial support from Elekta and personal fees from Wolters Kluwer, outside the submitted work. All other authors report no financial conflicts of interest.
- 1.Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1 CrossRefPubMedGoogle Scholar
- 2.Robinson DR, Wu Y-M, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung Y-S, Chen C-L, Zhang L, Wang R, Su F, Iyer MK, Roychowdhury S, Siddiqui J, Pienta KJ, Kunju LP, Talpaz M, Mosquera JM, Singer S, Schuetze SM, Antonescu CR, Chinnaiyan AM (2013) Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet 45: 180–185. http://www.nature.com/ng/journal/v45/n2/abs/ng.2509.html-supplementary-information
- 3.Chmielecki J, Crago AM, Rosenberg M, O’Connor R, Walker SR, Ambrogio L, Auclair D, McKenna A, Heinrich MC, Frank DA, Meyerson M (2013) Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet 45: 131–132. http://www.nature.com/ng/journal/v45/n2/abs/ng.2522.html-supplementary-information
- 4.Schweizer L, Koelsche C, Sahm F, Piro RM, Capper D, Reuss DE, Pusch S, Habel A, Meyer J, Göck T, Jones DTW, Mawrin C, Schittenhelm J, Becker A, Heim S, Simon M, Herold-Mende C, Mechtersheimer G, Paulus W, König R, Wiestler OD, Pfister SM, von Deimling A (2013) Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol 125:651–658. https://doi.org/10.1007/s00401-013-1117-6 CrossRefPubMedGoogle Scholar
- 5.Bouvier C, Metellus P, de Paula AM, Vasiljevic A, Jouvet A, Guyotat J, Mokhtari K, Varlet P, Dufour H, Figarella-Branger D (2012) Solitary fibrous tumors and hemangiopericytomas of the meninges: overlapping pathological features and common prognostic factors suggest the same spectrum of tumors. Brain Pathol (Zurich) 22:511–521. https://doi.org/10.1111/j.1750-3639.2011.00552.x CrossRefGoogle Scholar
- 6.Macagno N, Figarella-Branger D, Mokthari K, Metellus P, Jouvet A, Vasiljevic A, Loundou A, Bouvier C (2016) Differential diagnosis of meningeal SFT-HPC and meningioma: which immunohistochemical markers should be used? Am J Surg Pathol 40:270–278. https://doi.org/10.1097/pas.0000000000000526 PubMedGoogle Scholar
- 7.Fritchie KJ, Jin L, Rubin BP, Burger PC, Jenkins SM, Barthelmess S, Moskalev EA, Haller F, Oliveira AM, Giannini C (2016) NAB2-STAT6 gene fusion in meningeal hemangiopericytoma and solitary fibrous tumor. J Neuropathol Exp Neurol 75:263–271. https://doi.org/10.1093/jnen/nlv026 CrossRefPubMedGoogle Scholar
- 8.Savary C, Rousselet MC, Michalak S, Fournier HD, Taris M, Loussouarn D, Rousseau A (2016) [Solitary fibrous tumors and hemangiopericytomas of the meninges: Immunophenotype and histoprognosis in a series of 17 cases]. Ann Pathol 36:258–267. https://doi.org/10.1016/j.annpat.2016.06.002 CrossRefPubMedGoogle Scholar
- 11.Bisceglia M, Galliani C, Giannatempo G, Lauriola W, Bianco M, D’Angelo V, Pizzolitto S, Vita G, Pasquinelli G, Magro G, Dor DB (2011) Solitary fibrous tumor of the central nervous system: a 15-year literature survey of 220 cases (August 1996–July 2011). Adv Anat Pathol 18:356–392. https://doi.org/10.1097/PAP.0b013e318229c004 CrossRefPubMedGoogle Scholar
- 12.Zeng L, Wang Y, Wang Y, Han L, Niu H, Zhang M, Ke C, Chen J, Lei T (2016) Analyses of prognosis-related factors of intracranial solitary fibrous tumors and hemangiopericytomas help understand the relationship between the two sorts of tumors. J Neuro-Oncol. https://doi.org/10.1007/s11060-016-2282-y Google Scholar
- 13.Tihan T, Viglione M, Rosenblum MK, Olivi A, Burger PC (2003) Solitary fibrous tumors in the central nervous system. A clinicopathologic review of 18 cases and comparison to meningeal hemangiopericytomas. Arch Pathol Lab Med 127:432–439. https://doi.org/10.1043/0003-9985(2003)127003C0432:sftitc003E2.0.co;2 PubMedGoogle Scholar
- 15.Kinslow CJ, Rajpara RS, Wu C-C, Bruce SS, Canoll PD, Wang S-H, Sonabend AM, Sheth SA, McKhann GM, Sisti MB, Bruce JN, Wang TJC (2017) Invasiveness is associated with metastasis and decreased survival in hemangiopericytoma of the central nervous system. J Neuro-Oncol. https://doi.org/10.1007/s11060-017-2450-8 Google Scholar
- 17.Rutkowski MJ, Jian BJ, Bloch O, Chen C, Sughrue ME, Tihan T, Barani IJ, Berger MS, McDermott MW, Parsa AT (2012) Intracranial hemangiopericytoma: clinical experience and treatment considerations in a modern series of 40 adult patients. Cancer 118:1628–1636. https://doi.org/10.1002/cncr.26411 CrossRefPubMedGoogle Scholar
- 24.Carneiro SS, Scheithauer BW, Nascimento AG, Hirose T, Davis DH (1996) Solitary fibrous tumor of the meninges: a lesion distinct from fibrous meningioma. A clinicopathologic and immunohistochemical study. Am J Clin Oncol 106:217–224Google Scholar
- 29.Warren JL, Harlan LC (2003) Can cancer registry data be used to study cancer treatment? Med Care 41:1003–1005. https://doi.org/10.1097/01.mlr.0000086827.00805.b5 CrossRefPubMedGoogle Scholar
- 30.(released April 2016, based on the November 2015 submission) Surveillance, Epidemiology,and End Results (SEER) Program (http://www.seer.cancer.gov) SEER*Stat Database: Incidence- SEER 9 Regs Research Data, Nov 2015 Sub (1973–2013) < Katrina/Rita Population Adjustment>- Linked To County Attributes - Total U.S., 1969–2014 Counties.
- 33.Sonabend AM, Zacharia BE, Goldstein H, Bruce SS, Hershman D, Neugut AI, Bruce JN (2014) The role for adjuvant radiotherapy in the treatment of hemangiopericytoma: a Surveillance, Epidemiology, and End Results analysis. J Neurosurg 120:300–308. https://doi.org/10.3171/2013.10.jns13113 CrossRefPubMedGoogle Scholar
- 40.Lee EJ, Kim JH, Park ES, Khang SK, Cho YH, Hong SH, Kim CJ (2016) The impact of postoperative radiation therapy on patterns of failure and survival improvement in patients with intracranial hemangiopericytoma. J Neuro-Oncol 127:181–190. https://doi.org/10.1007/s11060-015-2030-8 CrossRefGoogle Scholar
- 42.Choi J, Park S-H, Khang SK, Suh Y-L, Kim SP, Lee YS, Kwon HS, Kang S-G, Kim SH (2016) Hemangiopericytomas in the central nervous system: a Multicenter Study of Korean Cases with validation of the usage of STAT6 immunohistochemistry for diagnosis of disease. Ann Surg Oncol. https://doi.org/10.1245/s10434-016-5414-x Google Scholar
- 46.Zhu H, Duran D, Hua L, Tang H, Chen H, Zhong P, Zheng K, Wang Y, Che X, Bao W, Wang Y, Xie Q, Gong Y (2016) Prognostic factors in patients with primary hemangiopericytomas of the central nervous system: a series of 103 cases at a single institution. World Neurosurg 90:414–419. https://doi.org/10.1016/j.wneu.2016.02.103 CrossRefPubMedGoogle Scholar